Somewhat Positive Media Coverage Somewhat Unlikely to Impact Aldeyra Therapeutics (NASDAQ:ALDX) Share Price

Media stories about Aldeyra Therapeutics (NASDAQ:ALDX) have been trending somewhat positive on Saturday, according to Accern Sentiment. The research group ranks the sentiment of press coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Aldeyra Therapeutics earned a coverage optimism score of 0.16 on Accern’s scale. Accern also assigned news stories about the biotechnology company an impact score of 46.1478053410011 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.

Shares of Aldeyra Therapeutics (ALDX) traded down 1.16% on Friday, hitting $4.25. 7,783 shares of the stock were exchanged. Aldeyra Therapeutics has a one year low of $3.80 and a one year high of $8.19. The company has a 50-day moving average price of $4.65 and a 200-day moving average price of $4.74. The firm’s market capitalization is $26.54 million.

Aldeyra Therapeutics (NASDAQ:ALDX) last posted its quarterly earnings data on Tuesday, August 8th. The biotechnology company reported ($0.35) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.37) by $0.02. Equities research analysts expect that Aldeyra Therapeutics will post ($1.63) earnings per share for the current year.

A number of equities research analysts have issued reports on the stock. Stifel Nicolaus restated a “buy” rating and set a $16.00 price target on shares of Aldeyra Therapeutics in a report on Wednesday, May 31st. Zacks Investment Research cut shares of Aldeyra Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, May 30th. HC Wainwright set a $18.00 price target on shares of Aldeyra Therapeutics and gave the company a “buy” rating in a report on Thursday, June 15th. Finally, Canaccord Genuity set a $12.00 price target on shares of Aldeyra Therapeutics and gave the company a “buy” rating in a report on Wednesday, June 14th. One analyst has rated the stock with a hold rating and four have given a buy rating to the stock. The stock has a consensus rating of “Buy” and an average price target of $14.15.

ILLEGAL ACTIVITY WARNING: “Somewhat Positive Media Coverage Somewhat Unlikely to Impact Aldeyra Therapeutics (NASDAQ:ALDX) Share Price” was originally posted by Community Financial News and is the sole property of of Community Financial News. If you are accessing this article on another domain, it was copied illegally and republished in violation of international copyright & trademark laws. The correct version of this article can be read at https://www.com-unik.info/2017/08/19/somewhat-favorable-news-coverage-somewhat-unlikely-to-affect-aldeyra-therapeutics-nasdaqaldx-share-price-updated.html.

In other Aldeyra Therapeutics news, major shareholder Life Sciences Maste Perceptive acquired 296,007 shares of the business’s stock in a transaction on Friday, June 30th. The stock was purchased at an average price of $4.60 per share, with a total value of $1,361,632.20. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Insiders own 28.40% of the company’s stock.

About Aldeyra Therapeutics

Aldeyra Therapeutics, Inc, formerly Aldexa Therapeutics, Inc, is a biotechnology company. The Company’s principal activities include raising capital and research and development activities. The Company’s segment is the identification and development of a treatment for diseases related to high levels of aldehydes.

Insider Buying and Selling by Quarter for Aldeyra Therapeutics (NASDAQ:ALDX)

What are top analysts saying about Aldeyra Therapeutics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Aldeyra Therapeutics Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit